Page 138 - 《中国药房》2023年9期
P. 138
to simvastatin treatment[J]. J Cardiovasc Pharmacol, genet Genomics,2017,27(8):285-293.
2020,75(2):168-173. [36] ZHANG L H,KAMANNA V S,GANJI S H,et al. Niacin
[24] SAŁACKA A,BOROŃ A,GORĄCY I,et al. An associa‐ increases HDL biogenesis by enhancing DR4-dependent
tion of ABCG8:rs11887534 polymorphism and HDL- transcription of ABCA1 and lipidation of apolipoprotein
cholesterol response to statin treatment in the Polish popu‐ A-I in HepG2 cells[J]. J Lipid Res,2012,53(5):941-950.
lation[J]. Pharmacol Rep,2021,73(6):1781-1786. [37] HU M,CHU W C,YAMASHITA S,et al. Liver fat reduc‐
[25] LIU M Y,FAN F F,ZHANG Y,et al. The association of tion with niacin is influenced by DGAT-2 polymorphisms
GATM polymorphism with statin-induced myopathy:a in hypertriglyceridemic patients[J]. J Lipid Res,2012,53
systematic review and meta-analysis[J]. Eur J Clin Phar‐ (4):802-809.
macol,2021,77(3):349-357. [38] HU M,YANG Y L,NG C F,et al. Effects of phenotypic
[26] CHAPMAN M J. Fibrates in 2003:therapeutic action and genotypic factors on the lipid responses to niacin in
in atherogenic dyslipidaemia and future perspectives[J]. Chinese patients with dyslipidemia[J]. Medicine (Balti‐
Atherosclerosis,2003,171(1):1-13. more),2015,94(20):e881.
[27] HOUSE J S,MOTSINGER-REIF A A. Fibrate pharmaco- [39] BAE J W,CHOI C I,LEE J H,et al. Effects of UDP-
genomics:expanding past the genome[J]. Pharmacoge‐ glucuronosyltransferase polymorphisms on the pharmaco‐
nomics,2020,21(4):293-306. kinetics of ezetimibe in healthy subjects[J]. Eur J Clin
[28] LIU Y J,ORDOVAS J M,GAO G M,et al. Pharmaco- Pharmacol,2011,67(1):39-45.
genetic association of the APOA1/C3/A4/A5 gene cluster [40] ALTMANN S W,DAVIS H R Jr,ZHU L J,et al.
and lipid responses to fenofibrate:the genetics of lipid- Niemann-Pick C1 Like 1 protein is critical for intestinal
lowering drugs and diet network study[J]. Pharmacogenet cholesterol absorption[J]. Science,2004,303(5661):
Genomics,2009,19(2):161-169. 1201-1204.
[29] WOJCZYNSKI M K,GAO G M,BORECKI I,et al. [41] LOU X Y,QIN C Z,BAO M H,et al. Analysis of
Apolipoprotein B genetic variants modify the response to Niemann-Pick C1-like 1 (NPC1L1) genetic polymor‐
fenofibrate:a GOLDN study[J]. J Lipid Res,2010,51 phisms and haplotypes in Chinese Han population[J].
(11):3316-3323. Pharmazie,2015,70(9):581-585.
[30] TSAI M Y,ORDOVAS J M,LI N,et al. Effect of fenofi‐ [42] ZSÍROS N,BODOR M,VARGA V,et al. The c.-133A >
brate therapy and ABCA1 polymorphisms on high-density G polymorphism in NPC1L1 gene influences the efficacy
lipoprotein subclasses in the Genetics of Lipid Lowering of ezetimibe monotherapy on apolipoprotein A1 in hyper‐
Drugs and Diet Network[J]. Mol Genet Metab,2010,100 lipidemic patients[J]. Pharmazie,2014,69(6):424-429.
(2):118-122. [43] PISCIOTTA L,FASANO T,BELLOCCHIO A,et al. Ef‐
[31] LIU Y J,ORDOVAS J M,GAO G M,et al. The SCARB1 fect of ezetimibe coadministered with statins in genotype-
gene is associated with lipid response to dietary and confirmed heterozygous FH patients[J]. Atherosclerosis,
pharmacological interventions[J]. J Hum Genet,2008,53 2007,194(2):e116-e122.
(8):709-717. [44] BERTHOLD H K,LAAKSONEN R,LEHTIMÄKI T,
[32] SHEN J,ARNETT D K,PARNELL L D,et al. The effect et al. SREBP-1c gene polymorphism is associated with
of CYP7A1 polymorphisms on lipid responses to fenofi‐ increased inhibition of cholesterol-absorption in response
brate[J]. J Cardiovasc Pharmacol,2012,59(3):254-259. to ezetimibe treatment[J]. Exp Clin Endocrinol Diabetes,
[33] CARLSON L A. Nicotinic acid:the broad-spectrum lipid 2008,116(5):262-267.
drug. A 50th anniversary review[J]. J Intern Med,2005, [45] KAWAMURA R,SAIKI H,TADA H,et al. Acute myocar‐
258(2):94-114. dial infarction in a 25-year-old woman with sitosterolemia
[34] ASLIBEKYAN S,STRAKA R J,IRVIN M R,et al. [J]. J Clin Lipidol,2018,12(1):246-249.
Pharmacogenomics of high-density lipoprotein-cholesterol- [46] TADA H,NOHARA A,INAZU A,et al. Sitosterolemia,
raising therapies[J]. Expert Rev Cardiovasc Ther,2013,11 hypercholesterolemia,and coronary artery disease[J]. J
(3):355-364. Atheroscler Thromb,2018,25(9):783-789.
[35] TUTEJA S,WANG L,DUNBAR R L,et al. Genetic coding (收稿日期:2022-10-20 修回日期:2023-03-24)
variants in the niacin receptor,hydroxyl-carboxylic acid (编辑:唐晓莲)
receptor 2,and response to niacin therapy[J]. Pharmaco‐
· 1152 · China Pharmacy 2023 Vol. 34 No. 9 中国药房 2023年第34卷第9期